Tag: Ocugen

A string of positive clinical readouts has given Ocugen a clear narrative to bring to ophthalmology’s biggest gatherings this month. ...

A €10 price target with the stock trading at €1.29. That 673% gap isn't a typo — it's the distance ...

A single drug that could treat inherited blindness regardless of which gene is broken — that is the audacious promise ...

Ocugen has quietly reshaped its financial outlook. In May, the company placed $130 million in convertible notes, carrying a 6.75% ...

Ocugen enters a make-or-break stretch that will test both its science and its stock. The gene therapy developer, which has ...

The clinical calendar is tightening for Ocugen, and the stock is starting to stir in anticipation. Shares closed the week ...

The divergence between Ocugen's scientific trajectory and its stock price has rarely been starker. The biotech's shares closed at €1.05 ...

Ocugen is betting that a single therapeutic can rewrite the rules for treating inherited retinal diseases. Its lead candidate, OCU400, ...

Ocugen’s stock has been on a rollercoaster, sliding 25% over the past month to trade at €1.18, but the company ...

Ocugen has parted ways with its chief medical officer just as the biotech enters a pivotal stretch for its lead ...